2026 Q2 Corporate Presentation Upcoming Events Past Events Featured Mar 16, 2026 Notice of the 10th Annual General Meeting 2026 Mar 16, 2026 Webcast Registration Mar 16, 2026 Jan 16, 2026 J.P. Morgan Healthcare Conference Jan 16, 2026 Jan 16, 2026 Dec 9, 2025 ASH Annual Meeting Dec 9, 2025 Dec 9, 2025 Nov 25, 2025 Corporate Day Hosted by Mirae Asset Nov 25, 2025 Nov 25, 2025 Nov 12, 2025 UBS Global Healthcare Conference Nov 12, 2025 Nov 12, 2025 Aug 1, 2025 2025 Extraordinary General Meeting Aug 1, 2025 Aug 1, 2025 Jun 4, 2025 NDR (Non-Deal Roadshow) Hosted by Samsung Securities Jun 4, 2025 Jun 4, 2025 May 30, 2025 UBS Asian Investment Conference 2025 May 30, 2025 May 30, 2025 May 13, 2025 Samsung Global Investors Conference 2025 May 13, 2025 May 13, 2025 Mar 28, 2025 2025 9th Annual General Meeting Mar 28, 2025 Mar 28, 2025 Mar 26, 2025 2024 Annual Result Conference Call Mar 26, 2025 Mar 26, 2025 Mar 21, 2025 Orum Therapeutics to Host Fourth Quarter 2024 Earnings Conference Call Mar 21, 2025 Mar 21, 2025 Nov 27, 2024 UBS Asia Healthcare Corporate Day - Hong Kong 2024 Nov 27, 2024 Nov 27, 2024 Oct 6, 2024 Orum Therapeutics to Hold Analyst Day in Korea Oct 6, 2024 Oct 6, 2024 Sep 30, 2024 Orum Therapeutics to Host a Global Media Conference Call for the IPO Sep 30, 2024 Sep 30, 2024 Mar 14, 2023 Orum Therapeutics Announces Three Presentations At AACR 2023 Mar 14, 2023 Mar 14, 2023 Dec 10, 2022 Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151 at ASH 2022 Dec 10, 2022 Dec 10, 2022 Dec 10, 2022 Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML, At ASH 2022 Dec 10, 2022 Dec 10, 2022 Apr 8, 2022 Orum Therapeutics Presents Preclinical Data At AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1 Apr 8, 2022 Apr 8, 2022